

ENANTA PIPELINE

Pharmaceuticals

PRODUCT CANDIDATE	DISCOVERY	PRECLIN	PHASE 1	PHASE 2	PHASE 3	LAUNCH	STATUS
HCV Protease inhibitor	paritaprevir-containing regimens						GT1 and GT4: Marketed by AbbVie
HCV Protease inhibitor	glecaprevir-containing pan-genotypic 2-DAA combo*						Marketed in the U.S. and EU by AbbVie; Japan NDA priority review ongoing
NASH & PBC FXR Agonist	EDP-305						Phase 1 study in healthy subjects and subjects with presumptive NAFLD*
RSV N-protein inhibitor	EDP-938						Preclinical
HBV Core inhibitor							Preclinical
NASH FXR Agonist follow-on							Preclinical
NASH Undisclosed							Discovery

*Fixed-dose combination contains glecaprevir and AbbVie's NS5A inhibitor, pibrentasvir

NOTE: "NAFLD" refers to non-alcoholic fatty liver disease; "presumptive NAFLD" means subjects who are obese and may also have pre-diabetes or type 2 diabetes.